[PDF] Top 20 Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs

... therapies. Breast cancer can be classified into three large subgroups: hormone receptor-positive, HER-2-positive (which is also hormone-receptor positive in less than half of cases), and the so-called ... See full document

... the treatment of TNBC remains an important ...still use standard CT (anthracyclines and ...the use of platinum-based CT in TNBC are now available, particularly in BRCA-mutation ... See full document

... for platinum- based ...to platinum agents, based on preclinical evidence that tumours harbouring BRCA deficiency are homologous recombination deficient and consequently, more sensitive to DNA damaging ... See full document

... the use of other therapeutic targets, such as αβ-crystallin, Sox2, embryonic transcription factor, osteopontin, phosphorylated glycoprotein, nestin and type 4 intermediate fi lament ...of platinum ... See full document

... To determine fibrosis and TGF-β activation in TNBC as a model, we used patient-derived xenograft (PDX) models that retain the essential features of the original patient tumors and metastasis to specific sites (HCI-001 ... See full document

... Abstract: Triple-negative breast cancer (TNBC), as a collective group of heterogenous tumours, displays the highest rate of distant recurrence and lowest survival from metastatic disease ... See full document

... of cancer cells suggested them as a surrogate biomarker for response to other therapies ...clinical use for the treatment of metastatic breast cancer are Liposomes-Doxorubicin nanodrug ... See full document

... The information input that is used nowadays in the clinic for patients with TNBC is not sufficient to distin- guish between patients who have a high chance to have a pCR when treated with conventional NACT from patients ... See full document

... a triple negative phenotype ...mutated breast cancer patients, DNA-repair instead of homologous recombination is per- formed by Base Excision Repair ...applied. Treatment with Olaparib ... See full document

... Patient and methods. In our retrospective analysis, we analized 431 patients with TNBC treated with combination therapy from March 2005 until December 2009 at the Institute of Oncology, Vilnius University. 52.20% of the ... See full document

... Background: Triple negative breast cancer is a subtype of breast cancer that shows minimal or no immunohistochemical expression of estrogens receptor, progesterone receptor and ... See full document

... of breast cancer was detected in the period from 12 to 60 months after the operative removal of the primary tumor (metachronous metastases); ECOG ...two treatment groups: 1) chemotherapy with ... See full document

... medical use in the United States in July 2004 ...antiangiogenic treatment might impact the intratumoural delivery of concurrently applied ...advanced breast cancer in 2011, BM remains in ... See full document

... The use of newer molecular techniques have and will continue to be very valuable in indentifying potential new molecules important for survi- val of neoplastic cells and that could potentially be tar- geted in the ... See full document

... At the same time, targeted delivery of platinum drugs with long-circulating liposomes also provides another efficient strategy to improve platinum drug efficacy with reduced toxicity. Liposomal drugs are ... See full document

... Quality assessment according to REMARK guidelines was performed for all 21 included studies. The studies fulfilled, on average, 14 items (range, 10–18 items) of the guidelines. Sensitivity and sub-group analyses were ... See full document

... classified according to three levels of etarfolatide uptake (ie, ++ , + , - ). The probability of a response was greater with + than with – lesions (P= 0.0022). The disease control rate was 57% ( ++ ), 36% ( + ), and 33% ... See full document

... the breast tissue and serum of women at an increased risk of breast cancer, ie, those with a previous history of carcinoma in situ or atypical hyperplasia, or an increased projected breast ... See full document

... non triple-negative cases in 84.6% of cases versus 80.1% of non-triple-negative ...in triple negative cases in ...the triple negative, for cons, a medium grade (SBR ... See full document

... of breast cancer samples [37]. The molecular subtypes of these breast cancer patients were defined by IHC staining of ER, PR, and ...being negative and a score of 2 to 8 being ...= ... See full document